Trecondyv is under clinical development by Medac and currently in Pre-Registration for Hematopoietic Stem Cell Transplantation. According to GlobalData, Pre-Registration drugs for Hematopoietic Stem Cell Transplantation have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Trecondyv’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Treosulfan (Trecondyv, Trecondi) is the prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. It is formulated as lyophilized powder, powder for solution for intravenous route of administration. Trecondyv is indicated in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT). Trecondi (treosulfan) in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases.
The drug candidate is under development for the treatment of allogeneic hematopoietic stem cell transplantation in the US.
medac is engaged in the development, manufacture and supply of medical solutions. The company’s offers diagnostic and therapeutic agents to diagnose and treat oncological, urological, dermatology, rheumatology, gastroenterology, autoimmune indications, concomitant and secondary diseases. It provides its products in the form of tablets, gels, capsules, and injections, among others. medac has expertise in strategic planning, pharmaceutical research and development, quality assurance pharmacovigilance, and others. The company serves patients, doctors, laboratory physicians and clinics. It operates in France, Italy, the UK, the US, Poland, Scandinavia, the Czech Republic, Japan, Finland, Portugal, Slovakia, and Denmark. medac is headquartered in Wedel, Schleswig-Holstein, Germany.
For a complete picture of Trecondyv’s drug-specific PTSR and LoA scores, buy the report here.